A A A A
 
Pages
How to Participate in Precision Panc Remit of Scientific Advisory Board Meeting Minutes Membership Remit of Therapeutic Testing Board Meeting Minutes Precision Panc Therapeutic Testing Board Membership Remit of Steering Committee Patient Stories Steering Group Members Therapeutic Testing Board Meetings PRIMUS 002 PRIMUS 001 Working with the NHS Patient Public Engagement Meetings Steering Committee Scientific Advisory Board Governance Structure Governance Master Protocol Kick Off Meeting News Clinicians Area Clinical Trials What is precision medicine? Information and Support What is Pancreatic Cancer? Research History Current Research Our Researchers Privacy Policy Patients and Carers Contact Us About us Home
Posts
CRUK animate the Precision-Panc platform CRUK / Precision-Panc Video Professor Biankin receives the Order of Australia in Queen’s Birthday Honours Precision-Panc opens its 20th Site Precision Panc Spring Newsletter Precision-Panc Opens Site 19 Recent Media Pieces Regarding 100 Patient Milestone Site 17 opens for Precision-Panc PRIMUS 002 opens Informing the Future of Genomic Medicine in Scotland Report is Published St James’s University Hospital Opens Precision-Panc Opens its 15th site Glasgow Experts Lead UK Pancreatic Cancer Research 11th site opens to PRECISION-Panc Scotsman Conferences Blogspot November is Pancreatic Cancer Awareness Month First Precision-Panc Trial Opens In Glasgow Cancer Research UK Investment Landscape of pancreatic neuroendocrine cancer Whole Genome Sequencing from EUS biopsies Upcoming Pancreas 2016 Conference Scottish Genome Partnership Announced Identification of four Pancreatic Cancer subtypes offers new treatment insight into the disease First Minister announces £4m ‘Precision Medicine Ecosystem’
Menu
 
 
Home | News | PRIMUS 002 opens

PRIMUS 002 opens

Published: 6th March 2019


A fantastic week for the Precision-Panc platform with the PRIMUS 002 trial opening to recruitment in Glasgow.

PRIMUS 002 is a study for pancreatic patients whose tumour has not spread outside the pancreas and who may be suitable for surgery

The trial will give the patients either FOLFOX-A or AG chemotherapy prior to surgery, hoping to shrink the tumour and ensure all the disease can be removed at time of surgery. The study will also do vital translational work to generate further knowledge on which types of tumour respond better to which treatments.

Study Chief Investigator Derek Grose said “The PRIMUS 002 trial is an exciting and very important step in Pancreatic Cancer research. This study will give vital information on the best way to treat patients with potentially operable Pancreatic Cancer in the future in attempt to improve the very poor outcomes that are currently seen.”

Over the next year PRIMUS 002 will open an further sites around the U.K. Please contact the Precision-Panc team for further information.

© 2019 Precision Panc
Web design by Creatomatic
This site uses cookies.
Configure
 
Read our privacy policy

This site uses cookies for marketing, personalisation, and analysis purposes. You can opt out of this at any time or view our full privacy policy for more information.